BioCurex CEO Highlights Recent Presentation of Its RECAF Test at ...
BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical... "The potential to monitor recurrence and perhaps the effectiveness of cancer therapy using only one blood test for all types of cancer makes the RECAF test broadly appealing. Moro made two presentations related to the Company's broad spectrum cancer marker, RECAF™, that is increased in the blood of cancer patients. Also, the fact that RECAF can detect cancers such as breast cancer, for which there are no good alternative markers, makes it more attractive. The second presentation discussed the statistical validation of new cancer markers based on the experience gathered while developing RECAF. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The meeting was broadly attended by scientists, physicians and biotechnology companies involved in cancer diagnostics. RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. Moro was asked to co-author a paper setting up guidelines related to the statistical validation of new tumor markers. These results together with other data indicate that the RECAF test can be used to monitor therapy and recurrence in cancer patients. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers. BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories (NYSE: ABT ) and with Inverness Medical Innovations. The technology identifies a universal cancer marker known as RECAF. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. "This was a very important meeting for BioCurex because of the interest elicited by our presentations," said Dr. Moro. The first presentation described the decrease in RECAF following removal of the tumor by surgery. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. (OTCBB: BOCX ) CEO Dr. Ricardo Moro recently presented at the meeting of the International Society of Oncology and BioMarkers (ISOBM) held on Sept. The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Forward-Looking Statements. 20, 2010 (GLOBE NEWSWIRE) -- BioCurex Inc. BioCurex, Inc....
Great tool 
love Sensimix:ELISA Kit for Rat Troponin C Type 1,Slow(TNNC1): love SENSIMIX biotechnology : love ELISA Kit for ...